The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia

International Clinical Psychopharmacology

Volumn 24, Issue 4, 2009, Pages 214-222

  Montgomery, Stuart A ^a   Herman, Barry K ^b   Schweizer, Edward ^c   Mandel, Francine S ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b PFIZER INC   (United States)

^c Paladin Consulting Group   (United States)

Author keywords

Efficacy; Generalized anxiety disorder; Insomnia; Placebo controlled trial; Pregabalin

Indexed keywords

ALPRAZOLAM; LORAZEPAM; PLACEBO; PREGABALIN; VENLAFAXINE;

ADULT; AMBLYOPIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; COORDINATION DISORDER; DAYTIME SOMNOLENCE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON RATING SCALE FOR ANXIETY; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; ANXIETY DISORDERS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; PLACEBOS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 67651207814     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832dceb9     Document Type: Article

References (36)

1. American Psychiatric Association (APA) (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: APA.
2. Andrews G, Slade T (2002). The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis. Psychopathology 35:100-106.
3. Ansseau M, Fischler B, Dierick M, Albert A, Leyman S, Mignon A (2008). Socioeconomic correlates of generalized anxiety disorder and major depression in primary care: the GADIS II study. Depress Anxiety 25:506-513.
4. Breslau N, Roth T, Rosenthal L, Andreski P (1996). Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 39:411-418.
5. 2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 28:75-82.
6. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23:240-249.
7. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
8. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
9. Herman BK, Mychaskiw MA, Mandel FS (2009). Comparison of sleep outcomes in generalized anxiety disorder following treatment with pregabalin or venlafaxine-XR. Poster presentation at the annual meeting of the American Psychiatric Association, San Francisco.
10. Hindmarch I, Dawson J, Stanley N (2005). A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 28:187-193.
11. Johnson EO, Roth T, Breslau N (2006). The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res 40:700-708.
12. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B (2007). Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 146:317-325.
13. Lipman R, Covi L (1976). Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer R, Klein DL, editors. Evaluation of the psychological therapies. Baltimore: Johns Hopkins University Press; pp. 178-218.
14. Manber R, Blasey C, Arnow B, Markowitz JC, Thase ME, Rush AJ, et al. (2005). Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries. J Psychiatr Res 39:481-488.
15. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC (2006). Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67: 771-782.
16. Monti JM, Monti D (2000). Sleep disturbance in generalized anxiety disorder and its treatment. Sleep Med Rev 4:263-276.
17. Ohayon MM, Roth T (2003). Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 37:9-15.
18. Olfson M, Shea S, Feder A, Fuentes M, Nomura Y, Gameroff M, Weissman MM (2000). Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med 9:876-883.
19. Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T (1994). Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA 272:1741-1748.
20. Pande AC, Crockatt JC, Feltner DE, Janney CA, Smith WT, Weisler R, et al. (2003). Pregabalin in generalized anxiety disorder: a placebo controlled trial. Am J Psychiatry 23:240-249.
21. Papadimitriou GN, Linkowski P (2005). Sleep disturbance in anxiety disorders. Int Rev Psychiatry 17:229-236.
22. Perlis ML, Kehr EL, Smith MT, Andrews PJ, Orff H, Giles DE (2001a). Temporal and stage-wise distribution of high frequency EEG activity in patients with primary and secondary insomnia and in good sleeper controls. J Sleep Res 10:93-104.
23. Perlis ML, Smith MT, Andrews PJ, Orff H, Giles DE (2001b). Beta/Gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. Sleep 24:110-117.
24. Pohl RB, Feltner DE, Fieve RR, Pande AC (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo controlled comparison of BID versus TID dosing. J Clin Psychopharm 25: 151-158.
25. Raskin A, Schulterbrandt J, Reatig N (1969). Replication of factors of psychopathology in interview, ward behaviour and self-report ratings of hospitalized depressives. J Nerv Ment Dis 148:87-98.
26. Rasmussen NH, Bernard ME, Harmsen WS (2008). Physical symptoms that predict psychiatric disorders in rural primary care adults. J Eval Clin Pract 14:399-406.
27. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. (2005). Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:1022-1030.
28. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV 3rd, Hahn SR, et al. (1994). Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA 272:1749-1756.
29. Staner L, Cornette F, Maurice D, Viardot G, Le Bon O, Haba J, et al. (2003). Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia. J Sleep Res 12:319-330.
30. Steiger A (2007). Neurochemical regulation of sleep. J Psychiatr Res 41:537-552.
31. Taylor CP, Garrido R (2008). Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha(2)-delta (alpha(2)-delta) type 1 protein. Neuroscience 155:510-521.
32. Taylor CP, Angelotti T, Fauman E (2007). Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73: 137-150.
33. Weissman MM, Greenwald S, Nino-Murcia G, Dement WC (1997). The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry 19:245-250.
34. Wilson S, Argyropoulos S (2005). Antidepressants and sleep: a qualitative review of the literature. Drugs 65:927-947.
35. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J (2002). Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63 (Suppl 8):24-34.
36. Zee PC, Manthena P (2007). The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med Rev 11:59-70.